तुलना करने के लिए मीट्रिक्स | 4891 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4891पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −9.0x | −6.4x | −0.2x | |
PEG अनुपात | −0.23 | −0.22 | 0.00 | |
क़ीमत/बुक | 2.2x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 15.5x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 349.3% | 133.1% | 65.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | −0.7% | 8.9% | अनलॉक करें |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.